Who is sponsoring NCT03704662?

NCT03704662 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT03704662?

Interventions in NCT03704662: Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy.

What condition does NCT03704662 study?

NCT03704662 studies Pancreatic Cancer.

Is NCT03704662 still recruiting?

NCT03704662 is currently recruiting now. Last updated 8 October 2025.

Last reviewed 2025-10-08 · How we verify

NCT03704662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Recruiting now NA Last updated 8 October 2025

What this trial tests

NA trial testing Stereotactic Body Radiation Therapy in Pancreatic Cancer in 102 participants. Currently enrolling.

Timeline

22 October 2018

Primary endpoint
1 June 2026

1 June 2031

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	102
Start date	22 October 2018
Primary completion	1 June 2026
Estimated completion	1 June 2031
Sites	1 location across United States

Drugs / interventions tested

Stereotactic Body Radiation Therapy — full drug profile →
Preoperative Fractionated Radiation Therapy and Chemotherapy

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Consensus, debate, and prospective on pancreatic cancer treatments.
Wang J, Yang J, Narang A, He J, et al · · 2024 · cited 56× · PMID 39390609 · DOI 10.1186/s13045-024-01613-x
Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
Seufferlein T, Ettrich TJ. · · 2019 · cited 35× · PMID 30976724 · DOI 10.21037/tgh.2019.03.05
Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.
Hall WA, Dawson LA, Hong TS, Palta M, et al · · 2021 · cited 28× · PMID 34623894 · DOI 10.1200/jco.21.01220
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Bouchart C, Navez J, Closset J, Hendlisz A, et al · · 2020 · cited 27× · PMID 32684987 · DOI 10.1177/1758835920936093
The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer.
Ghaly M, Gogineni E, Saif MW. · · 2019 · cited 22× · PMID 31930185 · DOI 10.17140/poj-3-110
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Bouchart C, Engelholm JL, Closset J, Navez J, et al · · 2021 · cited 18× · PMID 34691244 · DOI 10.1177/17588359211045860
Pancreatic cancer: new approaches to drug therapy.
Picozzi VJ. · · 2024 · cited 7× · PMID 38573111 · DOI 10.1097/js9.0000000000000877
Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.
de Jesus VHF, Riechelmann RP. · · 2023 · cited 7× · PMID 37115533 · DOI 10.1177/10732748231173212

Verify or expand the search:

Other trials of Stereotactic Body Radiation Therapy

Trials testing the same drug.

NCT07156227 — Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell · Phase 1 · not yet recruiting
NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
NCT07150715 — Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for th · Phase 2 · recruiting
NCT07150546 — Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. · Phase 1 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03704662 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 8 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing